Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Champions Oncology, Inc.

CSBR

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $4.56 – $4.71
Volume 4,350
Market cap $65M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$65.14M
Price / earnings
—
Price / book
16.73×
Price / sales
1.07×
EV / sales
1×
EV / EBITDA
151.57×

Profitability

Earnings per share
-$0.08
Return on assets
-3.32%
Return on equity
-28.36%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.03×
Quick ratio
1.03×
Cash ratio
0.23×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.14M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CSBR, quarterly periods
Line itemQ1 FY2027 Jul 31, 2026Q4 FY2026 Apr 30, 2026Q3 FY2026 Jan 31, 2026Q2 FY2026 Oct 31, 2025Q1 FY2026 Jul 31, 2025Q4 FY2025 Apr 30, 2025Q3 FY2025 Jan 31, 2025Q2 FY2025 Oct 31, 2024
Revenue$15.23M$13.84M$16.56M$15.04M$14M$12.36M$17.04M$13.49M
Cost of revenue$7.53M$6.81M$8.83M$7.26M$8M$7.27M$6.62M$7.43M
Gross profit$7.7M$7.03M$7.73M$7.77M$6M$5.08M$10.42M$6.06M
Selling, general and administrative$5.76M$5.43M$5.64M$4.97M$4.43M$4.84M$4.2M$3.64M
Research and development$2.34M$2.12M$2.27M$2.62M$2.08M$1.96M$1.72M$1.69M
Total operating expenses$8.11M$7.55M$7.91M$7.59M$6.53M$6.8M$5.92M$5.33M
Operating income-$409K-$521K-$187K$185K-$527K-$1.71M$4.5M$732K
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$415K-$495K-$237K$255K-$452K-$1.96M$4.52M$739K
Income taxes$11K$172K$42K$18K$14K-$129K$23K$11K
Net income-$426K-$667K-$279K$237K-$466K-$1.84M$4.5M$728K
Net income attributable to common shareholders-$426K-$667K-$279K$268K-$466K-$1.84M$4.5M$728K
EBITDA-$95K-$200K$154K$542K-$169K-$1.32M$4.9M$1.13M
Basic earnings per share-$0.03-$0.05-$0.02$0.02-$0.03-$0.13$0.33$0.05
Diluted earnings per share-$0.03-$0.05-$0.02$0.02-$0.03-$0.13$0.31$0.05

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Champions Oncology vs. Biodesix: Which Oncology Stock Is a Better Buy?

In a comparison of two oncology-focused healthcare companies, Champions Oncology (CSBR) is recommended as the better buy over Biodesix (BDSX). While BDSX has surged 156.7% over the past year, CSBR offers more attractive valuation metrics and better risk-reward positioning. CSBR benefits from strong demand for oncology research services, expanding data licensing opportunities, and radiopharmaceutical development initiatives. BDSX shows promise through lung diagnostic test adoption and operational improvements, but trades at a higher valuation with less upside potential.

Zacks Investment Research

CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth

Champions Oncology (CSBR) reported Q1 FY2027 revenues of $15.2 million, up 8.8% year-over-year, with improved margins and narrowed losses. However, the stock declined 1.8% post-earnings. The company saw strong growth in data-license revenues (up 187.1%) but faced headwinds from declining Other TOS revenues. Management emphasized continued investment in sales and marketing while pursuing funding or licensing partnerships for its Corellia platform.

The Motley Fool

Champions Oncology (CSBR) Earnings Transcript

Champions Oncology reported Q3 FY2026 results with record core study revenue of $16.6 million (up 32% YoY), but overall revenue declined 3% due to absence of data revenue. The company achieved its third consecutive quarter of positive adjusted EBITDA at $575,000. Gross margins fell to 47% from 61% due to $2M in outsourced radiolabeling costs. Management expects margin improvement as work moves in-house and anticipates full-year revenue growth and positive EBITDA, with early momentum in the data business including a 6-figure deal expected to recognize in Q4.

Benzinga

Insiders Buying Solid Biosciences And 2 Other Stocks

Although U.S. stocks closed mixed on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Solid Biosciences The Trade: Solid Biosciences Inc. (NASDAQ: SLDB) Director Joseph Edelman acquired a ...

Benzinga

Insiders Buying Tilly's And 2 Other Stocks

Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. General American Investors The Trade: General American Investors Company, Inc. (NYSE: GAM) President and CEO ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 12, 20151-for-12reverse split